Table 4.

Hemopure clinical trials

Patient Population	Control Dosage	HBOC Dosage	Physiologic Effects	Treatment Effect
Surgical Patients38	Allogeneic PRBC transfusion (n=24), PRN	(n=40), 60g, option of 3 more doses of 30g	↑ MAP, serum urea [N2], Bicarbonate, BE, plasma [Hb] ↓ Hct	↓ PRBC use in 27% of patients
Surgical Patients39	Allogeneic PRBC transfusion (n=48), PRN	(n=50), 60g, option of 3 more doses of 30g	↑ MAP, Mean PAP, arterial O2 ↓ CI, SpO2	↑ O2 extraction* ↓ PRBC use
Surgical Patients40	LR (n=26), 849 mL	(n=55), 0.6g/kg - 2.5g/kg	↑ plasma Hb	Intraoperative use of HBOC well tolerated
Surgical Patients42	Allogeneic PRBC transfusion (n=338), PRN	(n=350), 65g, up to 325g	↑ total [Hb], Hct	↑ cardiac adverse effects* ↓ PRBC use*

^* = p<0.05; all physiologic effects reported as statistically significant per the authors’ criteria, LR= lactated Ringer’s solution, RBC= red blood cells, PRBC= packed red blood cells, MAP= mean arterial pressure, BE= base excess, Hb= hemoglobin, Hct= hematocrit, PAP= pulmonary arterial pressure, CI= cardiac index